Krystal Biotech, Inc. KRYS Business Segments — SG&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s business segments — sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s business segments — SG&A?
- Krystal Biotech, Inc. (KRYS) reported business segments — SG&A of $41.01M in Q1 2026.
- How has Krystal Biotech, Inc.'s business segments — SG&A changed year-over-year?
- Krystal Biotech, Inc.'s business segments — SG&A increased by 25.6% year-over-year, from $32.65M to $41.01M.
- What is the long-term trend for Krystal Biotech, Inc.'s business segments — SG&A?
- Over 2 years (2023 to 2025), Krystal Biotech, Inc.'s business segments — SG&A has grown at a 22.2% compound annual growth rate (CAGR), from $98.29M to $146.83M.
- What does business segments — SG&A mean?
- The overhead and commercial costs required to run the business and sell products.
- How do you interpret business segments — SG&A?
- An increase often correlates with commercial expansion or market launch activities, while excessive growth relative to revenue may indicate inefficiency.
- How does business segments — SG&A compare across companies?
- SG&A typically scales as companies transition from clinical development to commercialization, reflecting the build-out of a sales force.